Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study
Mepolizumab treatment reduced HCRU while improving activity and productivity in patients with severe asthma over 2 years. These data provide further evidence of real-world benefits of mepolizumab and may help inform healthcare system resource allocation.
Authors
- Lingjiao Zhang (ORCID: https://orcid.org/0000-0003-0700-4584)
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- ARNAUD AB BOURDIN (ORCID: https://orcid.org/0000-0002-4645-5209)
- Peter Howarth (ORCID: https://orcid.org/0000-0003-0619-7927)
- Erika Dianne Penz (ORCID: https://orcid.org/0000-0003-2610-8450)
- Rafael Alfonso-Cristancho
Institutions
- Global Affairs Canada (CA)
- Humanitas University (IT)
- Université de Montpellier (FR)
- University of Saskatchewan (CA)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Global Medical Imaging (US)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Journal of Asthma
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1080/02770903.2025.2558755
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16